Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Finished Goods (2017 - 2019)

Avalo Therapeutics filings provide 3 years of Finished Goods readings, the most recent being $46705.0 for Q4 2019.

  • On a quarterly basis, Finished Goods fell 90.62% to $46705.0 in Q4 2019 year-over-year; TTM through Dec 2019 was $46705.0, a 90.62% decrease, with the full-year FY2019 number at $46705.0, down 90.62% from a year prior.
  • Finished Goods hit $46705.0 in Q4 2019 for Avalo Therapeutics, down from $497949.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $560499.0 in Q4 2017 to a low of $46705.0 in Q4 2019.
  • Median Finished Goods over the past 3 years was $497949.0 (2018), compared with a mean of $368384.3.
  • Biggest five-year swings in Finished Goods: decreased 11.16% in 2018 and later tumbled 90.62% in 2019.
  • Avalo Therapeutics' Finished Goods stood at $560499.0 in 2017, then dropped by 11.16% to $497949.0 in 2018, then tumbled by 90.62% to $46705.0 in 2019.
  • The last three reported values for Finished Goods were $46705.0 (Q4 2019), $497949.0 (Q4 2018), and $560499.0 (Q4 2017) per Business Quant data.